Benitec Biopharma
BNTC
4 hedge funds and large institutions have $337K invested in Benitec Biopharma in 2020 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
355% more capital inflows, than outflows
Capital inflows: $91.6K | Capital outflows: $20.1K
3.98% more ownership
Funds ownership: 0% → 3.98% (+4%)
0% more funds holding
Funds holding: 4 → 4 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$81.2K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$10.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$20.1K |
BNTC Hedge Fund Activity: Q2 2020 in Review
4 of the 4,890 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q2 2020, worth a combined $337K — up 70% from $198K a quarter earlier.
Fund positioning in BNTC was balanced in Q2 2020: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 1 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $81.2K. The largest seller was Sabby Management, cutting an estimated $20.1K.
- 4 institutional investors held Benitec Biopharma (BNTC) as of Q2 2020, unchanged from Q1 2020.
- Funds reported $337K of Benitec Biopharma stock for Q2 2020, up 70% quarter-over-quarter.
- 1 fund opened new Benitec Biopharma positions in Q2 2020 and 1 closed out, a net change of 0 holders.
- The largest Benitec Biopharma buyer in Q2 2020 was Morgan Stanley, an estimated $81.2K added.
- The largest Benitec Biopharma seller in Q2 2020 was Sabby Management, an estimated $20.1K sold.
Based on aggregated 13F filings for Q2 2020.